Long GV - Search Results

1

Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.

Menzies AM, Long GV. Menzies AM, et al. Among authors: long gv. Eur J Cancer. 2013 Oct;49(15):3229-41. doi: 10.1016/j.ejca.2013.06.027. Epub 2013 Jul 16. Eur J Cancer. 2013. PMID: 23870385 Review.

2

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Long GV, et al. J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343559

3

Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care.

Scolyer RA, Long GV, Thompson JF. Scolyer RA, et al. Among authors: long gv. Mol Oncol. 2011 Apr;5(2):124-36. doi: 10.1016/j.molonc.2011.03.002. Epub 2011 Mar 21. Mol Oncol. 2011. PMID: 21482206 Free PMC article. Review.

4

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Wilmott JS, et al. Among authors: long gv. Clin Cancer Res. 2012 Mar 1;18(5):1386-94. doi: 10.1158/1078-0432.CCR-11-2479. Epub 2011 Dec 12. Clin Cancer Res. 2012. PMID: 22156613

5

Treatment of melanoma brain metastases: a new paradigm.

Carlino MS, Fogarty GB, Long GV. Carlino MS, et al. Among authors: long gv. Cancer J. 2012 Mar-Apr;18(2):208-12. doi: 10.1097/PPO.0b013e31824b2890. Cancer J. 2012. PMID: 22453023 Review.

6

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Menzies AM, et al. Among authors: long gv. Clin Cancer Res. 2012 Jun 15;18(12):3242-9. doi: 10.1158/1078-0432.CCR-12-0052. Epub 2012 Apr 24. Clin Cancer Res. 2012. PMID: 22535154

7

Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma.

Murali R, Brown PT, Kefford RF, Scolyer RA, Thompson JF, Atkins MB, Long GV. Murali R, et al. Among authors: long gv. Cancer. 2012 Sep 15;118(18):4519-29. doi: 10.1002/cncr.27693. Epub 2012 Jun 26. Cancer. 2012. PMID: 22736239 Free article.

8

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, Scolyer RA, Long GV. Wilmott JS, et al. Among authors: long gv. Mol Cancer Ther. 2012 Dec;11(12):2704-8. doi: 10.1158/1535-7163.MCT-12-0530. Epub 2012 Sep 7. Mol Cancer Ther. 2012. PMID: 22962325

9

(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.

Carlino MS, Saunders CA, Haydu LE, Menzies AM, Martin Curtis C Jr, Lebowitz PF, Kefford RF, Long GV. Carlino MS, et al. Among authors: long gv. Eur J Cancer. 2013 Jan;49(2):395-402. doi: 10.1016/j.ejca.2012.08.018. Epub 2012 Sep 14. Eur J Cancer. 2013. PMID: 22981500 Clinical Trial.

10

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA. Long GV, et al. Am J Surg Pathol. 2013 Jan;37(1):61-5. doi: 10.1097/PAS.0b013e31826485c0. Am J Surg Pathol. 2013. PMID: 23026937

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

617 results

Search Page

Filters